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Serum amyloid P component (SAP) 1 is a normal plasma glycoprotein composed 
of non-covalently associated subunits arranged with cyclic pentameric symmetry 
in a  disk-like configuration.  It is a  member of the pentaxin family of proteins, 
which includes C-reactive protein (CRP), the classical acute phase reactant, and 
the homologues of CRP and SAP that exist in lower animals (1, 2). Although its 
biological function is unknown,  there are a  number of observations indicating 
that SAP is likely to be of both physiological and pathophysiological importance. 
First, there are proteins that closely resemble human SAP in terms of appearance 
in the electron microscope, subunit composition, and amino acid sequence in the 
sera of all vertebrates in which they have been sought (3-5). Second, a  protein 
that is immunochemically indistinguishable from SAP is a  normal integral con- 
stituent of the human glomerular basement membrane (6) and of the peripheral 
microfibrillar mantle  of elastic fibers throughout  the body (7).  Third,  both in 
man and lower animals SAP is laid down as amyloid P component (AP), a minor 
but significant constituent of all forms of amyloid deposits (8) with the possible 
exception of the intracerebral plaques in human Alzheimer's disease and senile 
dementia (9). 
In  addition  to  the  stable  evolutionary conservation  of structure  in  SAP  of 
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account of these findings was presented at the Medical Research Society meeting, 7 July 1983 (C. R. 
K. Hind et al. 1983. Clin. Sci. (Lond.). 65:17p). C. R. K. Hind is the recipient of a research fellowship 
from the Medical Research Council. Correspondence should be addressed to M. B. Pepys at the 
Immunological Medicine Unit, Department of Medicine, Royal Postgraduate Medical School, Ham- 
mersmith Hospital, Du Cane Road, London W12 0HS. 
1  Abbreviations used in this  paper: [a]D  temp, optical rotation; AP, amyloid P component; BSA, bovine 
serum albumin; pmax, frequency of infra-red absorption band; C4bp, C4-binding protein; CRP, C- 
reactive protein; cyclic  acetal MOBDG, methyl 4,6-O-(1-carboxyethylidene)-fl-D-galactopyranoside;  ~i, 
chemical shifts; Fn, fibronectin; J, coupling constants; NHS, normal human serum; NMR, nuclear 
magnetic resonance; non-cyclic  acetal MOBDG, methyl (4 or 6)-O-[(R,S)-I  '-carboxy-1  '-methoxy-eth- 
yl]4~-D-galactopyranoside;  PAGE, polyacrylamide gel electrophoresis; p.p.m., parts per million; Rf, 
spot mobility on t.l.c.; SAP, serum amyloid P component; signal multiplicities:  s, singlets; d, doublets; 
t, triplets; m, multiplets; t.l.c., thin layer chromatography; TMS, tetramethylsilane; Tris-saline-Ca, 
0.01 M Tris-buffered 0.138 M NaCI containing 0.002 M CaCI~ and 0.1% wt/vol NaNs at pH 8.0; 
Tris-saline°EDTA, 0.01 M Tris-buffered 0.138 M NaCI containing 0.01 M EDTA at pH 8.0. 
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different  species,  these  proteins  all  share  the  capacity  for  specific  calcium- 
dependent ligand binding.  This property was first discovered with respect to 
agarose (3,  10,  11) although earlier work on a then unidentified plasma glyco- 
protein (12), which was later shown to be SAP (13), had demonstrated its affinity 
for calcium ions.  It was then established that SAP binds to amyloid fibrils in a 
calcium-dependent interaction that probably underlies the in vivo deposition of 
AP (14).  Furthermore, in the presence of calcium, aggregated, but not native, 
human SAP selectively binds  fibronectin (Fn) and  C4-binding protein  (C4bp) 
from normal human serum (15). All these interactions are highly specific and it 
seems likely that  ligand  binding  by  SAP  participates  in  its  in  vivo function. 
Identification of the chemical nature of the ligand(s) should therefore help to 
explain the biological role of SAP and may also contribute to structural charac- 
terization of the protein itself. 
Although it is most improbable that binding of SAP to agarose is itself related 
to a physiological function of the protein, it has greatly facilitated the isolation 
and characterization of SAP from man and other animals and provides a model 
system suitable for chemical studies.  Agarose is a  linear galactan hydrocolloid 
derived from marine algae and composed of repeating units of agarobiose (1,3- 
1inked ~-D-galactopyranose and  1,4-1inked 3,6-anhydro-a-L-galactopyranose) to- 
gether with trace amounts of sulfate and pyruvate, the latter as the 4,6-pyruvate 
acetal of/3-D-galactopyranose (16, 17) (Fig.  1). There are large differences in the 
amounts of SAP that bind to beaded agarose gels from different sources (14), 
suggesting that  the actual  ligand for SAP in  agarose may be a  variable trace 
constituent of the polysaccharide. We report here that binding of SAP to gels 
prepared from a range of agaroses of known composition correlates closely with 
their  pyruvate  content,  but  not  at  all  with  the  amount  of sulfate  present. 
Methylation of the carboxylic acid of the pyruvate residues abolishes the binding 
of SAP. We have therefore synthesized a pyruvate acetal at the 4,6-positions of 
galactose, the form in which it exists in agarose, and have shown that it inhibits 
the calcium-dependent binding of SAP to agarose, to amyloid fibrils, to fibro- 
nectin, and to C4-binding protein. The availability of this chemically defined low 
molecular weight ligand should aid further work on SAP. 
Materials and Methods 
Agarose 
Agaroses of known pyruvate and sulfate content derived from Gelidium and Gracilaria 
species (kindly provided by FMC Corporation, Rockland, ME) were used to prepare a 4% 
wt/vol gel in 0.01 M Tris-buffered 0.138  M NaCI containing 0.002  M CaCI2 and 0.1% 
wt/vol NaN3 at pH 8.0 (Tris-saline-Ca). The gels were fragmented  into beads by sequential 
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FIGURE 1.  Agarobiose  showing the position of pyruvic  acid as the acetal 4,6-O-(1-carboxy- 
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passage through 710-gm and 80-gm sieves (Endecotts Ltd., London, England), and were 
stored in suspension in Tris-saline-Ca at 4°C. 
Diazomethane-treated  Aga rose 
Pyruvate-rich (0.25% wt/wt) agarose beads (4 ml packed volume) were added to 30 ml 
of  an ethereal solution of diazomethane (18) that had been diluted 1:1 vol/voi in methanol, 
and stirred for 60 rain at room temperature. After removal of the supernatant, the beads 
were washed with distilled water and then resuspended in Tris-saline-Ca. Control solvent- 
treated beads were mixed with identical volumes of ether/methanol (1:1 vol/vol) alone. 
Chemicals 
Methyl/3-D-galactopyranoside, methyl pyruvate, sodium pyruvate, and D-galactose were 
obtained from Sigma Chemical Co. Ltd., Poole, Dorset, England; ion exchange resin (IR 
120  H +) and  organic solvents from  BDH  Ltd.,  Dagenham,  Essex,  England  and  10% 
palladium on charcoal from Johnson Matthey Chemicals Ltd., Royston, Herts, England. 
Chemical Techniques 
all-Nuclear magnetic resonance (NMR) spectra were usually measured in CDCI3 with 
a JNM-FX200 Fourier transform NMR spectrometer (Jeol Ltd., Tokyo, Japan) or a WH- 
400  spectrometer (Bruker Ltd.,  Karlsruhe,  Federal Republic of Germany) with tetra- 
methyisilane  (TMS)  as  internal  standard.  Natural-abundance  ~SC-NMR spectra  were 
measured in CDC13 with JNM-FX60 or FX200 instruments (Jeol Ltd.) operating at 15 or 
50 MHz, respectively. The 1H-NMR spectra are presented as follows: chemical shifts (6) 
in parts per million (p.p.m.) downfield from TMS; signal  multiplicities (s, d,  t, m,  for 
singlets, doublets, triplets, muitiplets); signal  intensities (e.g. 3H); coupling constants in 
Hz (e.g. Jl.~ 3,0 Hz); signal assignment (e.g. H-2). For the 'SC-NMR  spectra the chemical 
shift is reported followed, where possible, by the signal assignment. 
Optical rotations ([aID  temp) were measured in chloroform with an AA-10 polarimeter 
(Optical  Activity Ltd.,  Huntingdon,  Cambridgeshire,  England).  Infrared spectra were 
measured (3'm~x recorded in cm  -l) with a 597 spectrometer (Perkin Elmer Ltd., Beacons- 
field, Bucks, England) on samples smeared on potassium bromide disks. 
Column chromatography was carried out on silica gel 230-400 mesh (Merck Kieselgel 
9385,  BDH  Ltd.).  For thin  layer chromatography (TLC) 0.25-ram  films  of silica  gel 
(Merck  Kieseigel 60  F2s4, BDH  Ltd.) were  used, and  the  spots were located with an 
ethanol 1% sulfuric acid spray reagent. The mobility of the spot relative to the mobility 
of the  solvent front (Rf) was  determined (19).  The  eluting  solvents were dried  over 
molecular sieves 4A (BDH Ltd.). 
Synthesis of acetals of Pyruvic Acid Derived from Methyl 13-D-Galactopyranoside 
Preparation of starting materials: Methyl pyruvate dimethyl acetal  (compound I)  was 
prepared by heating methyl pyruvate under reflux with methanol in the presence of IR 
120H  + ion exchange resin. Methyl 2,3-di-O-benzyl-/3-D-galactopyranoside  (compound II) 
was prepared by standard procedures from methyl 4,6-O-benzylidene-B-D-galactopyrano- 
side (20). 
Condensation of methyl 2,3-di-O-benzyl-/3-D-galactopyranoside  with methyl pyruvate: Compound 
II (1 g) was dissolved in compound I (9 ml) at 20°C. The solution was cooled to 0°C and 
concentrated sulfuric acid (0.1  ml) added with stirring. The solution was maintained at 
20°C under reduced pressure (0.1  mm Hg) for 4 h when TLC (40:60 vol/vol petroleum 
ether)  showed  several  intense  spots  in  the  range  R  l  0.1-0.5  and  a  little  unchanged 
compound II (R: 0.0).  The acid was  then neutralized by stirring the solution with an 
excess of anhydrous sodium hydrogen carbonate (NaHCO3) added in portions during 3 
h. Dichloromethane (1 1) was then added and the solution filtered. The filtrate was washed 
with aqueous NaHCOs and, after drying, evaporated to give a crude residue that was 
separated by column chromatography on silica gel with toluene, toluene/ethyl acetate 
(9:2 vol/vol) as an increasingly polar elutant. The major product was methyl 2,3-di-O- 
benzyl-4,6-O-[(R)-l-methoxycarbonylethylidene]-~-D-galactopyranoside (compound  III) HIND  ET  AL.  1061 
(642 rag); 1H-NMR (200 MHz) data: 4.17 (d, IH, J~.2 7.5 Hz, H-l), 3.52 (s, 3H, aglycone 
OCH3), 3.78 (s, 3H, CO~CH3), 1.58 (s, 3H, CH3C), 7.1-7.4 (m, 10H) and 4.65-4.92 (m, 
4H)  (2  ×  CH2C6Hs), plus  signals  for six  galactose protons.  In a  similar, larger  scale 
experiment using 5  g  of compound II, a  new major product was  isolated (2.3  g)  by 
chromatography using  toluene,  toluene/ethyl acetate  (9:2  vol/vol),  ethyl acetate  as 
increasingly polar elutants. It has been tentatively identified as methyl 2,3-di-O-benzyl-(4 
or  6)-O-(R,S-l'-methoxycarbonyl-l'-methoxy-ethyl)-3-~galactopyranoside  (compound 
IV). Details of the 1H and lSC-NMR results may be obtained from the authors. 
Hydrogenolysis  of methyl 2,3-di-O-benzyl-B-o-galactopyranoside  acetals of methyl pyruvate: Com- 
pound III (642 mg) in ethyl acetate (60 ml) containing 10% palladium on charcoal (150 
mg) was shaken for 2 h under 2.5 atmospheres of hydrogen. The catalyst was filtered off, 
and the filtrate evaporated to give methyl 4,6-0-[(R)-1-methoxycarbonylethylidene]-3-D- 
galactopyranoside (compound V)  (415  mg),  1H-NMR  (200  MHz)  data:  3.80  (s,  3H, 
COnCHs), 3.56 (s, 3H, aglycone OCH3),  1.63 (s, 3H, CCH3). The mixed, non-cyclic acetal 
(compound IV) (228 mg) was similarly hydrogenolyzed to give methyl (4 or 6)-0-[(R,S)- 
l'-methoxycarbonyl-l'-methoxy-ethyl]-3-r~galactopyranoside  (compound VI) (141  mg). 
I  13  Details of the  H and  C-NMR results may be obtained from the authors. 
Saponification of methyl 3-D-galactopyranoside  acetals of methyl pyruvate: The cyclic acetai 
methyl ester (compound V) (225 mg) was placed in 1.0 M aqueous sodium hydroxide (0.4 
ml) at 23 °C for 24 h~ and then the pH adjusted to 7.4 with 1.0 M hydrochloric acid. This 
solution of the sodium salt of the acetal was used without further characterization. The 
mixed non-cyclic acetal methyl ester (compound VI) (141 mg) was similarly treated. 
Proteins 
Isolated pure SAP (21) and Fn (22) were prepared from normal human serum (NHS) 
and citrated human plasma, respectively, according to established methods. Isolated pure 
C4bp (23) was the generous gift of Dr. V. Nussenzweig, New York University, New York. 
Bovine serum albumin (BSA) was obtained from Sigma Chemical Co. Ltd. 
Serum 
Fresh NHS was obtained by allowing venous blood from laboratory volunteers to clot 
at room temperature for 2-4 h before centrifugation. In some experiments, serum from 
a single donor was used, in others different sera were pooled. Acute phase mouse serum 
was obtained by exsanguination of MRL mice 48 h after subcutaneous injection of 0.5 ml 
2%  wt/voi AgNO3  solution. Pooled normal plaice  serum (Pleuronectes platessa L.) was 
kindly provided by Dr.  Thelma C.  Fletcher, NERC, Institute of Marine Biochemistry, 
Aberdeen. 
Antisera 
Monospecific antisera to human SAP and Fn, and to mouse and plaice SAP were raised 
by immunization of sheep and rabbits with the isolated pure proteins (24, 25). 
Assay of SAP and Fn 
Specific  protein  concentrations were  measured  by  electroimmunoassay (26)  using 
standards of the isolated pure proteins. 
PAGE 
Gradient PAGE analysis  of native proteins was performed in  4-30%  gradient gels 
(Pharmacia, Uppsala, Sweden), run exactly according to the manufacturer's instructions 
(15). 
Immobilized Proteins 
Human SAP was coupled to CNBr-activated Sepharose 4B (Pharmacia) (SAP-Sepharose, 
10 mg/ml) in pH  9.0 carbonate buffer precisely as described elsewhere (15).  Control 
BSA-Sepharose beads (10 mg/ml) were prepared as before (15). 1062  BINDING  SPECIFICITY  OF  SERUM  AMYLOID  P  COMPONENT 
Isolation of Amyloid Fibrils 
Fibrils from the spleen of a patient with reactive systemic (AA) amyloidosis were isolated 
(27) and lyophilized from distilled water. 
Binding of SAP to Agarose Beads and to Amyloid Fibrils 
Known amounts of agarose beads and, in different experiments, of amyloid fibrils were 
equilibrated with Tris-saline-Ca and then tested for SAP binding from serum exactly as 
described  elsewhere  (14).  Elution  with  the  chemicals  under  test  was attempted  using 
solutions in Tris-saline-Ca.  In other  experiments these solutions  were added  to serum 
before it was offered to either pyruvate-rich agarose beads (0.25% wt/wt) or fibrils. Tris- 
saline-EDTA was used as a control for complete elution or inhibition of binding of SAP. 
Binding of Fn and C4bp by Immobilized Human SAP 
The experimental procedure for demonstration of binding of Fn and C4bp from NHS 
by immobilized SAP has been described previously (15). Solutions in Tris-saline-Ca of the 
chemicals under test were used to either elute bound  Fn and C4bp or to inhibit  their 
uptake. Eiuates in Tris-saline-EDTA from SAP-Sepharose columns were tested by gradient 
PAGE and by specific electroimmunoassay for Fn. 
Results 
Amount of SAP Binding to Different Agaroses of  Known Composition.  The quantity 
of SAP from human,  mouse, and plaice serum that bound to different agaroses 
correlated closely with the pyruvate content of the agarose (human, r  =  0.92,  n 
--  11, P  <  0.001;  mouse, r =  0.95,  n  -  4, P  <  0.01; plaice, r  =  0.98,  n  =  4, P  < 
0.001; Fig. 2). There was no significant correlation between SAP bound and the 
sulfate content  (human,  r  -- 0.26,  n  =  11;  mouse,  r  =  0.73,  n  =  4;  plaice, r  = 
0.68, n =  4). Very little SAP bound to agarose gels that contained extremely low 
levels (0.01%  wt/wt) of pyruvate. 
Effect of Methylation of the Carboxylic Acid Residues in Agarose.  Prior  treatment 
of the  agarose beads with diazomethane completely abolished  their capacity to 
bind SAP (Table I). Treatment of beads by solvents alone had no effect. 
Synthesis of Pyruvate Acetals of Methyl 13-o-Galactopyranoside.  Methyl  4,6-0-(1- 
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FIGURE  2.  Capacity of different  agaroses of known  pyruvate  content  to  bind  human  (a), 
mouse (b), and plaice (c) SAP. HIND  ET  AL. 
TABLE  I 
Binding of  Human, Mouse, and Plaice SAP to Pyruvate-rich  Agarose 
Beads* 
Agarose  Human SAP  Mouse SAP  Plaice SAP 
mean +  SD, 
n=12 
Control  100 _+ 4  104  88 
Solvent treated  118 -4- 8  128  80 
Diazomethane treated  0  0  0 
* Expressed as #g SAP per 1 ml of packed agarose beads. 
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FIGURE 3. 
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Comparison of the structures of the cyclic acetal MO3DG (a) and the non-cyclic 
methoxycarbonylethylidene)-/3-o-galactopyranoside was  synthesized and  identi- 
fied as the R  isomer (compound V) on the basis of its IH-NMR spectrum (28). 
This was then saponified to give methyl 4,6-O-(1-carboxyethylidene)-/3-o-galac- 
topyranoside (the cyclic acetal MO/SDG; Fig. 3 a), the form in which the pyruvate 
acetal of galactopyranose exists in agarose. In another experiment, a mixed non- 
cyclic methyl pyruvate acetal  of methyl /~-D-galactopyranoside was synthesized 
and partially  identified as compound VI  on the basis of its  IH and  13C-NMR 
spectra.  This  was  also  saponified  to  give  methyl  (4  or  6)-O-(1 '-carboxy-1 '- 
methoxy-ethyl)-/3-I)-galactopyranoside (the  non-cylic acetal  MO/3DG;  Fig.  3b). 
The solutions of these acetals were then corrected to pH 7.4. In the subsequent 
binding experiments, these solutions were used either in this form or further 
diluted in Tris-saline-Ca. 
Inhibition of SAP Binding  to  Agarose by  Synthesized Galactosides.  Binding  of 
human, mouse and plaice (Table II) SAP to pyruvate-rich agarose was inhibited 
by the presence of MO/3DG.  The  R  isomer of the cyclic acetal  MO/3DG  was 
more  potent  than  the  non-cyclic  MO/3DG.  For  all  further  experiments  with 
human SAP the R isomer of the cyclic acetal MO/3DG was therefore used. Methyl 
/~-D-galactopyranoside, pyruvic acid, and D-galactose, all at concentrations of 1- 
2 ×  10 -2 M, had no appreciable effect on the binding of human, mouse, or plaice 
SAP. 
Elution of SAP  from Agarose by Synthesized Galactosides.  MO/3DG eluted human, 
mouse, and  plaice  (Table  III)  SAP  that  had  already  bound  to  pyruvate-rich 
agarose. Again, the R isomer of the cyclic acetal MO/3DG was more potent than 
the  non-cyclic  MO/~DG.  Methyl  /3-o-galactopyranoside,  pyruvic  acid,  and  D- 1064  BINDING SPECIFICITY OF  SERUM  AMYLOID  P  COMPONENT 
TABLE  II 
Inhibition of Binding of SAP to Agarose by MO/3DG 
Inhibition  of SAP 
Chemical  Concentration  binding 
% 
Human 
MOflDG, R isomer  7.63 x  10  -3 M  95 
7.63 ×  10  -4 M  60 
7.63 × 10  -~ M  0 
Non-cyclic MOBDG  6.82 X 10  -3 M  52 
6.82 × 10  -4 M  0 
MO~DG, R isomer 
Mouse  Plaice 
5 X 10  -3 M  100  73 
5 X 10  -4 M  60  15 
5× 10-SM  0  0 
TABLE  III 
Elution of  SAP  from Agarose by MO[3DG 
Chemical  Concentration  SAP eluted 
% 
Human 
Tris-saline-EDTA  control 
MOI3DG, R isomer 
Non-cyclic MOI3DG 
100 
7.75 X 10  -3 M  91 
7.75 X 10  -4 M  66 
7.75 X 10  -5 M  0 
2.04 ×  10  -~ M  66 
2.04 ×  10  -5 M  42 
2.04 ×  10  -4 M  0 
Tris-saline-EDTA  control 
MOI3DG, R isomer 
Mouse  Plaice 
100  100 
3.8 ×  10  -~ M  100  100 
5.4 ×  10  -3 M  74  21 
5.4 X 10  -4 M  20  0 
5.4 ×  10  -5 M  0  0 
galactose, all at  1-2 ×  10 -2 M, did not elute human, mouse, or plaice SAP that 
had already bound to agarose. 
Effect  of the  Cyclic acetal  MOI3DG on  Binding  of Fn  and  C4bp  by  saP-Sepha- 
rose.  When  added  to  fresh  NHS  before  mixing with  SAP-Sepharose,  the  R 
isomer of the cyclic acetal MO/3DG inhibited the binding of both Fn and C4bp. 
This was shown by immunoassay of Fn (Table IV) and gradient PAGE analysis 
of the  subsequent Tris-saline-EDTA eluate from  the  SAP-Sepharose.  In other 
experiments, the R  isomer of the cyclic acetal MO/3DG eluted Fn (Table V) and 
C4bp that were already bound by SAP-Sepharose, the gradient PAGE profile of 
these eluates being identical to that of the Tris-saline-EDTA eluates (15). 
Effect of  the Cyclic  Acetal MOI3DG on Human SAP Binding to Amyloid Fibrils.  When 
increasing amounts of the R  isomer of the cyclic acetal MO/3DG were added to 
NHS  before  being  offered  to  AA  amyloid  fibrils,  there  was  a  progressive HIND  ET  AL. 
TABLE  IV 
Effect of the Cyclic Acetal MO[3DG on the Capacity of SAP-Sepharose to 
Bind Fn 
Total Fn eluted* 
BSA- 
SAP-Seph-  Sepha- 
arose  rose 
ug 
Control: 
Tris-saline-Ca  45  0 
MOflDG, R isomer (7.66 ×  10  -s M)  0  0 
* NHS was offered to SAP-Sepharose in the presence of MOflDG, or Tris- 
saline-Ca as control, and after washing with Tris-saline-Ca was eluted 
with Tris-saline-EDTA. 
TABLE  V 
Elution of Fn from SAP-Sepharose by the Cyclic Acetal MO[3DG 
MOflDG, R isomer concentration 
Fn eluted: percent of 
amount eluted by 
Tris-saline-EDTA 
1.15 x  10  -2 M  100 
2.23 ×  10  -s M  85 
1.15 x  10  -s M  85 
2.3 ×  10  -4 M  67 
1065 
TABLE  VI 
Effect of the Cyclic Acetal MOI3DG on the Binding of Human SAP to 
Amyloid Fibrils 
Human SAP eluted with  MOflDG, R isomer concentration  Tris-saline-EDTA 
% 
0  100 
5.5 x  10  -5 M  78 
5.5 x  10 -4 M  56 
5.5 ×  10  -3 M  50 
reduction in the amount  of SAP bound  (Table VI). In other experiments, the R 
isomer of the cyclic acetal MOflDG  eluted human  SAP that  had already bound 
to the AA amyloid fibrils (Table VII). No elution was observed with methyl fl-D- 
galactopyranoside, pyruvic acid, or D-galactose at concentrations  between  10 -4 
and2×  10 -2M. 
Discussion 
The  present results show clearly that the amount  of SAP that binds to agarose 
gels is directly related to their pyruvate content. SAP scarcely binds at all to gels 
that  either  have  been  prepared  from  pyruvate-free  agarose  or  in  which  the 
carboxylic  moiety  of  the  pyruvate  has  been  methylated  by  treatment  with 1066  BINDING  SPECIFICITY  OF  SERUM  AMYLOID  P  COMPONENT 
TABLE VII 
Elution of Human SAP from Amyloid Fibrils by the Cyclic Acetal 
MOODG 
SAP eluted 
Chemical  Concentration  off 1 mg 
fibrils 
% 
Control: 
Tris-saline-EDTA 
MOBDG, R  isomer 
100 
1.15 ×  10  -2 M  65 
1.15 X  10 -3 M  35 
1.15  ×  10  -4 M  14 
diazomethane. The  pyruvate residues in  agarose  exist as  the acetal  4,6-O-(1- 
carboxyethylidene)-13-D-galactopyranose. In order to test the hypothesis that this 
material is  in  fact the  ligand  in  agarose  recognized by  SAP  and  to  obtain  a 
defined low  molecular weight  ligand  for  SAP,  we  synthesized methyl 4,6-0- 
(1-carboxyethylidene)-li-o-galactopyranoside (the  cyclic  acetal  MO/3DG)  from 
methyl 4,6-O-(1-methoxycarbonylethylidene)-/i-D-galactopyranoside (compound 
V), which we obtained by a shorter route than the one previously reported (29). 
Analysis of 1H-NMR spectra of this product showed it to be identical to the R 
isomer of compound V as reported by Garegg et al. (28). Subsequent saponifi- 
cation of this material yielded the cyclic acetal of MOIiDG.  This product was 
able both to inhibit binding of human, mouse, and plaice SAP to pyruvate-rich 
agarose and to elute SAP that was already bound. The effective concentration 
(10-3-10 -2  M)  was  comparable  to  the  calculated  concentration  of pyruvate 
residues in the pyruvate-rich agarose gel (1.66  ×  10 -3 M).  The importance of 
the fixed stereochemistry of the cyclic acetal ring in these binding experiments 
is emphasized by the lower potency of the non-cyclic MOI3DG.  The inherent 
flexibility of this non-cyclic form (Fig.  3) presumably results in a poorer stereo- 
alignment for SAP  to  bind.  Pyruvate or  D-galactose alone had  no  inhibitory 
effects on SAP binding, nor did methyl/3-D-galactopyranoside. Further work is 
required to determine which parts of the structure of these acetals of MO/3DG 
are most important for its recognition by SAP, but the methylation experiments 
suggest that the carboxyl group of the pyruvate residue may be critical. 
The binding of SAP to agarose is presumably fortuitous and not in any way 
directly related to the physiological function of the protein. Binding to amyloid 
fibrils (14)  and the more recently discovered interaction between aggregated 
SAP and Fn and C4bp (15) are probably of greater physiological and pathophys- 
ioiogical  importance.  It  is  therefore of considerable  interest  that  millimolar 
concentrations of the R  isomer of the cyclic acetal MOIiDG inhibited all these 
reactions.  The  ligands  for  SAP  expressed  by autologous proteins  apparently 
share some structural similarity with agarose and with MO/iDG, but the resem- 
blance does not necessarily reside in a carbohydrate moiety, since amyloid fibrils 
consist exclusively of nonglycosylated polypeptide chains (30). A possible candi- 
date for the polypeptide structure recognized by SAP is the so-called 13-turn, 
which is thought to exist in amyloid fibrils at the point where the fibril subunit HIND  ET  AL.  1067 
proteins, whether of AA, AL, prealbumin, or other origin, fold back on them- 
selves to form the anti-parallel/3-pleated  sheets that characterize amyloid (31). 
The 13-turn forms when there are many glycine residues appropriately distributed 
among bulky hydrophobic L-amino acids, and it is a  10-atom hydrogen-bonded 
ring inserted into the polypeptide backbone so that the end peptide moiety has 
its peptide acyl oxygen directed nearly perpendicular to the plane of the other 
atoms (32). This is an exposed position in which it is capable of binding cations, 
and  sequences that  form B-turns bind  calcium ions with high selectivity over 
other metallic cations (32).  Amyloid fibrils are  known to bind calcium (33) as 
does elastin, the first protein in which 13-turns were described (32). It is therefore 
notable that in man normal elastic fibers throughout the body bear SAP on their 
surface (7).  Both  Fn and C4bp bind calcium ions and it  is possible that their 
structures also contain 13-turns. 
The functional significance of the existence throughout vertebrate evolution 
of a plasma protein equipped under certain circumstances to recognize and bind 
/3-turns in other proteins and/or the pyruvate acetal of galactose in carbohydrates 
of autologous or extrinsic  origin remains  obscure.  However,  identification of 
MO/3DG as a low molecular weight ligand for SAP should assist investigation of 
this question.  Furthermore the complete amino acid sequences of both human 
(34) and mouse SAP (35) have recently been elucidated and it should be possible 
to use MOI3DG to localize the binding sequence in SAP. 
SUITlmary 
Serum  amyloid  P  component  (SAP)  is  a  normal  plasma  protein  that  is  of 
interest because of its presence in amyloid deposits, its presence in normal human 
glomerular basement membrane, and its stable evolutionary conservation. It has 
calcium-dependent  ligand-binding specificity for amyloid fibrils, fibronectin (Fn), 
C4-binding protein  (C4bp),  and  agarose.  Although the binding to agarose,  a 
linear galactan hydrocolloid derived from some marine algae, is unlikely per se 
to be related to the physiological function of SAP, it does provide a model system 
in which to explore the precise ligand requirements of SAP. We report here that 
the  amount  of SAP  from  human,  mouse, and  plaice (Pleuronectes platessa L.) 
serum  able  to  bind  to  agarose  from  different  sources  reflect  precisely  their 
pyruvate content. Methylation with diazomethane of the carboxyl groups in the 
pyruvate moiety of agarose completely abolishes SAP binding to agarose. 
The pyruvate  in agarose  exists as  the  4,6-pyruvate  acetal  of 13-D-galactopy- 
ranose. We have therefore synthesized this galactoside, using a novel procedure, 
established its structure  by analysis of its nuclear  magnetic resonance spectra, 
and  shown  that  it  completely  inhibits  all  known  calcium-dependent  binding 
reactions of SAP.  The R  isomer of the cyclic acetal,  methyl 4,6-O-(1-carboxy- 
ethylidene)-13-D-gaiactopyranoside (MOI3DG) was effective at millimolar concen- 
tration  and  was  more  potent  than  its  noncyclic analogue,  while  pyruvate,  D- 
galactose, and methyl/3-D-galactopyranoside were without effect. 
The  autologous  protein  ligands  of  SAP  presumably,  therefore  express  a 
structural determinant(s) that stereochemically resembles MOI3DG. Availability 
of this specific, well-characterized, low molecular weight ligand for SAP should 
facilitate further investigation of the function of SAP and its role in physiological 1068  BINDING SPECIFICITY OF  SERUM AMYLOID  P  COMPONENT 
and pathophysiological processes. 
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